SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.04
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.92

05 May
2026

0.090

OPEN

$2.89

3.18%

HIGH

$2.97

18,579,183

LOW

$2.88

TARGET
$3.229

+0.01 change from previous day

 10.6% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 5.1 6.4 xxx
DPS (cps) xxx 1.8 4.1 xxx
EPS Growth xxx 100.0% 25.5% xxx
DPS Growth xxx 82.7% 100.0% xxx
PE Ratio xxx N/A 46.0 xxx
Dividend Yield xxx N/A 1.4% xxx
Div Pay Ratio(%) xxx 35.6% 64.6% xxx

Dividend yield today if purchased 3 years ago: 2.57%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.62

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 0.5c (franking 50%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx5.1
DPS All xxxxxxxxxxxxxxx1.8
Sales/Revenue xxxxxxxxxxxxxxx14,404.4 M
Book Value Per Share xxxxxxxxxxxxxxx40.6
Net Operating Cash Flow xxxxxxxxxxxxxxx598.8 M
Net Profit Margin xxxxxxxxxxxxxxx8.83 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-
Return on Assets xxxxxxxxxxxxxxx-
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-
Free Cash Flow ex dividends xxxxxxxxxxxxxxx60.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx194 M
Long Term Debt xxxxxxxxxxxxxxx1,877 M
Total Debt xxxxxxxxxxxxxxx2,071 M
Goodwill - Gross xxxxxxxxxxxxxxx3,617 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx139 M
Price To Book Value xxxxxxxxxxxxxxx7.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx57.6 M
Capex % of Sales xxxxxxxxxxxxxxx0.40 %
Cost of Goods Sold xxxxxxxxxxxxxxx10,948 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,606 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx80 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.6

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

2

xxxxxxxxx xx xxxxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

05/05/2026

1

Buy

$3.40

16.44%

Sigma Healthcare has delivered a trading update for sales at Chemist Warehouse, revealing sales for the weeks 1-43 were up 16.7% in total and up 14.4% like-for-like.

UBS remains bullish on the outlook for health and beauty sales, noting the company is avoiding rising fuel costs and not experiencing any material disruption in its ability to source or deliver products.

The company has also entered into an MOU with Greenlight, an employee-owned pharmacy group in the UK, to license the Chemist Warehouse brand and intellectual property.

Phase 1 will be focused on rebranding up to 5 stores and in phase 2 more stores are planned and Sigma to acquire a 75% interest if these are successful. UBS raises the target to $3.40 from $3.35 and retains a Buy rating.

FORECAST
UBS forecasts a full year FY26 dividend of 4.00 cents and EPS of 6.00 cents.
UBS forecasts a full year FY27 dividend of 5.00 cents and EPS of 7.00 cents.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

06/05/2026

1

Buy

$3.60

23.29%

Jarden reiterates its Buy rating and $3.60 target price for Sigma Healthcare after the company reported accelerating top-line sales growth and announced a capital-light entry into the UK market.

Domestic momentum remained strong through the second half, with Chemist Warehouse (AU) sales growth picking up to +17.1% year-on-year in March and April due to store expansions, share gains, and structural health tailwinds.

The broker views the new 75% joint venture with London-based GreenLight Pharmacy as a sensible expansion strategy, providing immediate access to 22 locations and existing licenses with zero initial equity cost.

This allows the company to deploy its Every Day Low Price (EDLP) and multi-buy model into an underpenetrated market where competitors currently charge premiums.

Earnings forecasts are maintained, though the broker notes modest upside risk to margin expectations as the company scales its operations and integrates its newly announced $40m New Zealand distribution centre.

FORECAST
Jarden forecasts a full year FY26 dividend of 3.80 cents and EPS of 6.40 cents.
Jarden forecasts a full year FY27 dividend of 4.60 cents and EPS of 7.70 cents.
Access Extra Coverage Research History >

SIG STOCK CHART

FNArena News on SIG

1
April In Review: An Inflection Point

10:30 AM - Australia
2
Australian Broker Call *Extra* Edition – May 04, 2026

May 04 2026 - Daily Market Reports
3
Rudi’s View: More Downgrades Are Coming

Apr 29 2026 - Rudi's View
4
Rudi’s View: Best Buys & Conviction Calls

Apr 23 2026 - Rudi's View
5
Weekly Ratings, Targets, Forecast Changes – 17-04-26

Apr 20 2026 - Weekly Reports

Latest Health & Nutrition News

1
The Defensive Proposition Of Sigma Healthcare

Mar 30 2026 - Australia
2
Sigma Healthcare’s Four Pillars Of Growth

Aug 29 2025 - Australia
3
Sigma Healthcare: Synergies, Margins In Focus

Jun 19 2025 - Australia
4
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
5
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
6
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
7
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
8
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
9
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
10
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI